Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.

HOME
>
論文・技術情報
>
Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.

Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.

アブストラクト	OBJECTIVES: Enzalutamide, a second-generation anti-androgen drug, is an androgen receptor inhibitor developed to overcome resistance to first-generation anti-androgens, such as bicalutamide. This study aimed to identify previously undisclosed adverse events associated with enzalutamide. METHODS: Adverse reactions following enzalutamide administration were extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, and the data obtained were from 2014 to 2023. Four algorithms, namely ROR, PRR, BCPNN, and EBGM, were used to detect signs of adverse reactions associated with enzalutamide use. RESULTS: This study determined several adverse reactions in the nervous system, including hypogeusia, ageusia, dysgeusia, normal-pressure hydrocephalus, dementia, amnesia, balance disorders, and seizure-like phenomena. The mental aspects manifested as laziness, confusion, and eating disorders. Gastrointestinal system-related adverse reactions included dysphagia, constipation, fecal hardening, and abdominal discomfort. We identified several previously unreported adverse reactions, including normal-pressure hydrocephalus, dementia, balance disorders, eating disorders, and dysphagia. CONCLUSION: Our study revealed novel adverse events associated with enzalutamide, particularly in the nervous system, that have not been previously documented. These findings have important implications for future clinical medication guidelines.
ジャーナル名	Expert opinion on drug safety
Pubmed追加日	2023/9/6
投稿者	Wang, Xin; Chang, Lina; Li, Zhenhua; Jiang, Yuanfang; Chen, Yue; Jia, Xinli; Wang, Qiye; Ren, Xiaolu; Ma, Zhifang; Zhang, Wei
組織名	Department of Urology, First Hospital of Shanxi Medical University, Taiyuan,;Shanxi, China.;Shanxi Provincial Hospital of Traditional Chinese Medicine, Department of;Physician Standardization Training Center, Taiyuan, Shanxi, China.;Shanxi Hospital Affiliated to Cancer Hospital, Cancer Hospital, Shanxi Province;Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Medical University,;Taiyuan, Shanxi, China.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/37670490/